Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.
Oppenheimer upgrades Relay Therapeutics (RLAY) to Outperform, citing the strength of its mutant-selective inhibitor pipeline and upcoming catalysts in the breast cancer treatment arena.
In a bold marketing move, telehealth company Hims & Hers is leveraging the Super Bowl's massive audience to spotlight healthcare inequality with its 'Rich People Live Longer' campaign. The push comes as the company expands into advanced diagnostics and treatments, while its stock navigates a significant valuation gap after recent volatility.
A new bilateral trade agreement between the United States and Guatemala aims to eliminate tariffs and streamline preferential treatment for textiles and apparel, a move hailed by U.S. industry leaders as a strategic step to reinforce regional manufacturing networks and counter Asian dominance.
A federal judge has ordered the release of a five-year-old boy and his father from immigration detention, sparking a public clash between Trump administration officials and Democratic lawmakers over the family's asylum status and the treatment of migrant children.
A Minnesota judge orders the release of Liam Conejo Ramos and his father from a Texas ICE facility, citing 'traumatizing children' in pursuit of deportation quotas. The case sparked national outrage over the treatment of asylum-seeking families.
A five-year-old boy and his father are back in Minneapolis after a federal judge ordered their release from a Texas family detention center, a case that has ignited fierce debate over immigration enforcement tactics and the treatment of migrant children.
Usama Ghanem, an Egyptian student at King's College London, faces imminent deportation after disciplinary action linked to his pro-Palestinian activism. He claims the university's response mirrors the political persecution he fled in Egypt, raising urgent questions about academic freedom and the treatment of international dissent.
A 25-year-old Johnstown woman faces 18 felony counts, including arson endangering lives, after investigators say she intentionally set a duplex fire that forced residents to leap from second-story windows to escape.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
Investor Kevin O'Leary delivers a blunt message to young entrepreneurs: glorifying overwork is not a badge of honor but a strategic liability. He advocates for sleep, nutrition, and exercise as the real drivers of founder optimization.
The surge in popularity of weight-loss drugs like Ozempic and Wegovy is sending shockwaves far beyond the pharmacy, fundamentally altering consumer spending, challenging major corporations, and forcing a broad economic recalibration.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
In a rare show of unity, Pennsylvania's political leaders from both parties are rallying behind the state's famed weather-predicting groundhog, pushing back against an animal rights group's call to replace the living animal with a digital projection.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
